Category: pyrimidines

Epoxy compounds usually have stronger nucleophilic ability, because the alkyl group on the oxygen atom makes the bond angle smaller, which makes the lone pair of electrons react more dissimilarly with the electron-deficient system. Compound: 5-Methylfuran-2(3H)-one, is researched, Molecular C5H6O2, CAS is 591-12-8, about Characterization of key aroma-active compounds in four commercial oyster sauce by SGC/GC x GC-O-MS, AEDA, and OAV.Safety of 5-Methylfuran-2(3H)-one.

Oyster sauce (OS) is a common seasoning in Asian countries. Here, four types of OS with different components and ingredients were characterized by the switchable GC/GC x GC-olfactometry-mass spectrometry (SGC/GC x GC-O-MS) and sensory evaluation. A total of 27 key aroma-active compounds were screened by FD factor and OAVs in OS. Of them, pyrazines were predominated, 2,5-dimethyl-3-ethylpyrazine had the highest OAV and FD factor. Sensory evaluation showed that the overall flavor profile of OS is primarily composed of nutty/roast, caramel/sweet, cooked potato-like, fruity, burnt, and unpleasant notes such as rancid, mushroom-like, and fishy. Moreover, soy sauce exhibited a great impact on OS aroma. The principal component anal. (PCA) results based on the OAV values of key aroma-active compounds were consistent with the sensory evaluation results, suggesting that PCA based on the above method could accurately cluster and distinguish the samples with different aroma profiles. The odor notes of burnt, fruity and caramel-like/sweet contributed to WDM and JC clustering. Similarly, roast/nutty, cooked potato-like, and unpleasant odor notes contributed to clustering of LKK and HT.

If you want to learn more about this compound(5-Methylfuran-2(3H)-one)Safety of 5-Methylfuran-2(3H)-one, you may wish to communicate with the author of the article,or consult the relevant literature related to this compound(591-12-8).

Reference:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

The reaction of an aromatic heterocycle with a proton is called a protonation. One of articles about this theory is 《Synthesis of 2,4-dimethyl-3-hydroxy-5-hydroxymethylpyridine》. Authors are Balyakina, M. V.; Rubtsov, I. A.; Zhdanovich, E. S.; Preobrazhenskii, N. A..The article about the compound:5-(hydroxymethyl)-2,4-dimethylpyridin-3-ol hydrochloridecas:148-51-6,SMILESS:OC1=C(C)C(CO)=CN=C1C.[H]Cl).Reference of 5-(hydroxymethyl)-2,4-dimethylpyridin-3-ol hydrochloride. Through the article, more information about this compound (cas:148-51-6) is conveyed.

2,4-Dimethyl- 3 – hydroxy-5- hydroxymethylpyridine (4- deoxypyridoxine) (I) was synthesized via the following intermediates: 2,4-dimethyl-5-cyano-6-pyridone (II), 2,4-dimethyl-3-nitro-5-cyano-6-pyridone (III), and 2,4-dimethyl-3-nitro-5-cyano-6-chloropyridine (IV). Reduction of IV was carried out in 1 step in dilute HCl over Pd-C. 2,4-Dimethyl-3-amino-5-aminomethylpyridine was converted without isolation to I by treatment with NaNO2. Thus, 33 ml. NH4OH (d20 0.9) was added with stirring to 40 g. EtO2CCH2CN, the mixture cooled with ice to 0-2° and the precipitate filtered off, washed at 0° with 20 ml. cold EtOH, and dried to yield 23.8 g. cyanoacetamide (V), m. 120-2°. The filtrate was evaporated to dryness to yield an addnl. 3.95 g. Acetylacetone (10.0 g.) was added at 70° to 8.4 g. V in 50 ml. MeOH and 1.12 ml. Me2NH to precipitate 88.1% II, m. 293.1-4.2°. A suspension of 4.44 g. II in 15 ml. Ac2O is treated with stirring with 2.3 ml. HNO3 (d20 1.4) and 2.3 ml. Ac2O at 35-40°, and the mixture stirred 2 hrs. at 18-20° and poured upon 23 g. crushed ice, to precipitate 56.4% yellow III, m. 272.0-2.6° (alc.). P2O5 (5.3 g.) is added to a suspension of 3.6 g. III in 36 ml. PhCl, the mixture heated with stirring 3 hrs. at 118-120° the solvent removed at 45-50°/10 mm., the residue treated with 3.6 ml. absolute alc., stirred, and left 8 hrs. at 0-4°, the precipitate filtered off, washed at 0° with 2 ml. alc., and dried, and the residue extracted with petr. ether (b. 60-70°) to give 62.2% yellow IV, m. 114-15°. IV (2.4 g.) in 25 ml. ice water was added to a pre-hydrogenated mixture of 0.10 g. PdCl2 with H2O, HCl, and C, the hydrogenation continued until the theoretical H absorption, the catalyst separated and washed with 2 ml. H2O, 2.4 ml. HCl (d20 1.18) added to the solution and washings, and the solution heated 1.5 hrs. at 80-5° during which 1.6 g. NaNO2 in 5 ml. H2O was added, the heating continued 30 more min. (neg. starch-iodide test), the solution evaporated in vacuo, the residue extracted with absolute alc., the extracts treated with activated C and concentrated until the appearance of crystals, the mixture kept 8 hrs. at 0-4°, and the precipitate filtered off, washed at 0° with 1 ml. alc., and dried to give 42.2% I, m. 256.1-7.2°.

If you want to learn more about this compound(5-(hydroxymethyl)-2,4-dimethylpyridin-3-ol hydrochloride)Reference of 5-(hydroxymethyl)-2,4-dimethylpyridin-3-ol hydrochloride, you may wish to communicate with the author of the article,or consult the relevant literature related to this compound(148-51-6).

Reference:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

In general, if the atoms that make up the ring contain heteroatoms, such rings become heterocycles, and organic compounds containing heterocycles are called heterocyclic compounds. An article called Aminoalkylphenols as antimalarials. II. (Heterocyclic amino)-α-amino-ο-cresols. The synthesis of camoquin, published in 1948, which mentions a compound: 18436-73-2, Name is 4-Chloro-8-methylquinoline, Molecular C10H8ClN, SDS of cas: 18436-73-2.

In view of the high antimalarial activity of certain substituted α-amino-ο-cresols, earlier work (C.A. 41, 414d) has been extended to analogs containing heterocyclic nuclei. This reports the preparation of a group of 122 (heterocyclic amino)-α-amino-ο-cresols and a related group of 12 (heterocyclic amino)benzylamines, as well as the new intermediates used therein. This work has resulted in the preparation of a promising antimalarial (SN 10,751) named camoquin, as well as other compounds which are the most active 4-aminoquinoline derivatives heretofore reported in trophozoite-induced Plasmodium gallinaceum infection in the chick. Catalytic reduction of the appropriate nitrophenol in the presence of Ac2O gave these 4-acetamidophenols: 2-Cl, m. 144°, 55% yield; 2-Ph, m. 160°, 60%; and 2-acetamidophenols: 4-Cl, m. 186°, 52%; 4-Ph, m. 165°, 89%; and 4-tert-Bu, m. 170°, 79%. 2-Allyl-4-acetamidophenol, m. 93-4°, was obtained in 83% yield from the rearrangement of 4-CH2:CHCH2OC6H4NHAc. The Mannich reaction on the substituted acetamidophenols gave these 4-acetamido-α-substituted-ο-cresols: diethylamino (I), m. 135°, 82%; dibutylamino, m. 73°, 87% (picrate, m. 183-5°); dibenzylamino, m. 230°, 75%; (2-methyl-1-piperidyl) (HCl.H2O, m. 175°, 65%); 4-morpholinyl, m. 133°, 27%; [methyl(2-hydroxyethyl)amino] (HCl, m. 198°, 50%); (2-butylamino), m. 156°, 37%; (2-hydroxyethylamino) (HCl, m. 230°, 31%); the 6-allyl derivative of I, m. 86°, 58%: the 5-acetamido isomer of I (HCl, m. 210°, 33%); and these 6-acetamido-α-diethylamino-4-substituted-ο-cresols: Cl (HCl, m. 212°, 66%); tert-Bu (HCl, m. 158°, 53%); and Ph (HCl, m. 183°). Acid hydrolysis of the appropriate 4-acetamido compound gave these 4-amino-α-substituted-ο-cresols (di-HCl salts) (all m. with decomposition); diethylamino, SN 12,458, m. 218-20°, 96%; 1-piperidyl, m. 153-5°, 91%; and 4-morpholinyl, m. 259-60°, 45%. The Mannich reaction on 4-nitrophenol (A) and the reaction of the amine on 2-(chloromethyl)-4-nitrophenol (B) were used to prepare these α-substituted-4-nitro-ο-cresol HCl salts (all m. with decomposition): diethylamino, A, m. 224°, 40%; diisopropylamino, B, m. 193°, 19%; dibutylamino, B, m. 176°, 75%; diisobutylamino (free base), B, m. 113°, 43%; diisoamylamino, B, m. 132°, 32%; isopropylamino, B, m. 238°, 38%; isobutylamino, B, m. 247°, 29%; tertbutylamino, B, m. 275°, 20%; 1-piperidyl, A, m. 260°, 68%; and α-diethylamino-4-nitro-6-phenyl-ο-cresol, A, m. 125°, 21%; and 4-tert-butyl-α-diethylamino-6-nitro-ο-cresol, A, m. 103°, 50%. The method of Price and Roberts (C.A. 40, 5739.5) was used to prepare these substituted 4-chloroquinolines: 6-Me, m. 55°, 50%; 6-anilino, m. 148°, 6%; 7-EtO, m. 76°, 53%; 7-hexyloxy, a high-boiling liquid, 41%; 8-Me, m. 99°, 71%; 5,7-di-Me, m. 59°, 51%; 5,8-di-Me, m. 51°, 59%; 5-chloro-8-methoxy, m. 127°, 6%; 5-methyl-8-methoxy, m. 78°, 45%; 6,8-di-Me, m. 90°, 82%; and 6,7,8-trichloro, m. 156°, 39%. The (heterocyclic amino)-α-alkylamino-ο-cresols were prepared by minor variations of the general procedure of heating the chloroheterocycle with the amino-α-alkylamino-ο-cresols in aqueous or alc. solution on the steam bath. The latter were obtained either by acid hydrolysis of the acetamido derivatives or by catalytic reduction of the nitro derivatives and were usually condensed without isolation. The products are isolated either as the free bases or HCl salts. All the quinine equivalents (Q) reported here are based on the B4 test using P. gallinaceum in the chick. Nearly all the HCl salts m. with decomposition and are colored yellow to orange. 4-(4-Quinolylamino)-α-diethylamino-ο-cresol (II) di-HCl, SN 12,452, m. above 300°, was obtained in 48% yield and had a quinine equivalent of 3 (designated hereafter in the form Q 3). Analogs of II, substituted on the quinoline nucleus: 2-Cl (2HCl, SN 11,986, m. 248°, 30%, Q <0.07); 3-Ph, SN 11,631, m. 155°, 31%, Q 0.4; 6-MeO (2HCl, SN 10,274, m. 270°, 75%, Q 8); 6-Cl (HCl.0.5H2O, SN 11,597, m. 220°, 60%, Q 3.0); 6-Me, SN 11,559, m. 172° (2HCl, m. 238°, 56%, Q 4); 6-anilino (2HCl.H2O, SN 12,361, m. 196°, 63%, Q 0.2); 6-dimethylamino (3HCl.0.5H2O, SN 11,984, m. 235°, 73%, Q 2.5); 6-nitro (2HCl.1.5H2O, m. 210°, 63%, Q 0.8); 7-MeO (2HCl.0.5H2O, SN 11,554, m. 210°, 43%, Q 7); 7-EtO (2HCl.2H2O, SN 11,281, m. 136°, 44%, Q 7); (7-hexyloxy, SN 11,634, m. 153°, 35%, Q 0.5; Q 7); 7-Me (2HCl, SN 12,699, m. 245°, 93%, Q 9); 7-Cl (camoquin) SN 10,751, m. 208°, 86%, Q 25 (2HCl.0.5H2O, m. 243°); 2HCl.H2O, m. 183°; (2HCl.2H2O, m. 160°, 90%); 8-Cl, SN 11,551, m. 212° (2HCl.0.5H2O, m. 253°, 79%, Q 0.5); 8-MeO (2HCl.1.5H2O, SN 11,594, m. 241°, 50%, Q 0.8); 8-Me (2HCl.H2O, SN 11,601, m. 253°, 66%, Q 0.7); 5-chloro-3-Me (2HCl, SN 11,985, m. 258°, 48%, Q 0.3); 5,7-di-Cl (2HCl, SN 12,700, m. 200°, 65%, Q 3); 5,7-di-Me (2HCl, SN 11,561, m. 242°, 67%, Q 10); 5,8-di-Cl (2HCl.H2O, SN 11,596, m. 235°, 60%, Q 0.25); 5,8-di-Me (2HCl, SN 11,560, m. 249°, 80%, Q 0.6); 5-chloro-8-methoxy [2HCl, SN 12,162,(incorrectly given as 12,161 in original), m. 231°, 80%, Q 0.4]; 6-methoxy-2-Me (2HCl, SN 9223, m. 278°, 45%, Q 1.2); 6-methoxy-2-Ph (2HCl.1.75H2O, SN 11,592, m. 198°, 61%, Q 0.25); 6,7-di-Cl (2HCl, SN 12,161, m. 257°, 71.5%, Q 5); 6,7-di-MeO (2HCl, SN 13,395, m. 258°, 68%, Q 2.5); 6,7-di-Me, SN 11,990, m. 215°, 49%, Q 6; 6,8-di-Me (2HCl.H2O, SN 11,558, m. 264°, 54%, Q 0.6); 7-chloro-2-Ph (2HCl, SN 11,232, m. 260°, 41%, Q 0.3); 7-chloro-3-Ph, SN 12,228, m. 165°, Q 1; 7-chloro-3-Me (2HCl, SN 10,492, m. 260°, 64%, Q 6); 8-methoxy-5-Me (2HCl, SN 11,632, m. 210°, 90%, Q 0.6); 6,7,8-tri-Cl (2HCl, SN 11,633, m. 277°, 40%, Q <0.3); and 6-HO (2HCl, SN 11,563, m. 262°, 64%, Q 0.2) (prepared by HBr demethylation of the 6-MeO derivative). 4-(6-Methoxy-4-quinolylamino)-α-dibutylamino-ο-cresol (III) (2HCl.1.25H2O, m. 193°, 10%, Q 9); the (7-chloro-3-methyl-4-quinolylamino) analog of III (2HCl.1.5H2O, m. 177°, 43%, Q 10). 4-(6-Methoxy-4-quinolylamino)-α-1-piperidyl-ο-cresol (IV) (2HCl.0.5H2O, SN 12,038, m. 270°, 80%, Q 8); analogs of IV: (6,7-dimethoxy-4-quinolylamino) (2HCl, SN 13,413, m. 230°, 40%, Q 4); (7-chloro-3-methyl-4-quinolylamino) (2HCl, SN 12,360, m. 270°, 47%, Q 2); (6-methyl-4-quinolylamino) (2HCl, SN 12,456, m. 240°, 41%, Q 2.5). 4-(6-Methoxy-4-quinolylamino)-α-4-morpholinyl-ο-cresol (V) (2HCl, SN 11,989, m. 265°, 57%, Q 1); analogs of V: (7-chloro-3-methyl-4-quinolylamino) (2HCl, SN 12,362, m. 242°, 33%, Q 0.15); (6-methyl-4-quinolylamino), SN 12,457, m. 239°, 50%, Q 0.8. 5-(7-Chloro-4-quinolylamino)-α-diethylamino-ο-cresol, SN 13,730, m. 173°, Q 9; 6-(7-chloro-4-quinolylamino)-α-diethylamino-4-(diethylaminomethyl)-ο-cresol-1.5H2O, m. 145°, Q 5; 4-chloro-α-diethylamino-6-(6-methoxy-4-quinolylamino)-ο-cresol (2HCl, SN 12,885, m 205°, 50%, Q 0.5). 6-Chloro-4-(7-chloro-4-quinolylamino)-α-diethylamino-ο-cresol (VI), SN 13,729, m. 225°, Q 12; analogs of VI: 6-Ph (0.5H2O, m. 235°, 25%); 6-allyl, SN 11,991, m. 148°, 44%, Q 10; 6-allyl-α-1-piperidyl, SN 12,697, m. 190°, 32%, Q 4; 6-allyl-α-diallylamino, SN 13,394, m. 131°, 25%, Q 0.7. 6-Allyl-α-diethylamino-4-(6-methoxy-4-quinolylamino)-ο-cresol, SN 12,039, m. 161°, 33%, Q 7. Variations of the alkylamino group on the cresol portion of camoquin were studied: α-amino-4-(7-chloro-4-quinolylamino)-ο-cresol (VII) (2HCl.0.5H2O, SN 1603, m. 325°, 80%, Q 6); analogs of VII (substituents on the α-amino group): benzoyl (HCl, SN. 11,557, m. 289°, 80%, Q 0.15); Et (2HCl, m. 280°, Q 40, 4% conversion, prepared by the Mannich reaction of EtNH2, (HCHO)x, and 7-chloro-4-(4-hydroxyanilino)quinoline (HCl, m. above 320°, 94%)); Pr(2HCl.0.5H2O, m. 244°, 24%, Q 30); iso-Pr (2HCl, m. 287° 50%, Q 40); Bu (2HCl, m. 254°, 6%, Q 30); sec-Bu (2HCl.H2O, m. 252°, 3%, Q 50); iso-Bu (2HCl, m. 256°, 65%, Q 75); tert-Bu (2HCl, m. 285°, 36%, Q 40); Am (2HCl, m. 266°, 15%, Q 50); (1-methylbutyl 2HCl, m. 231°, 22%, Q 40); iso-Am (2HCl, m. 279°, 20%, Q 50); hexyl (2HCl, m. 280°, 56%, Q 25); (2-ethylbutyl (2HCl, m. 263°, 15%, Q 50)); heptyl (2HCl, m. 278°, 29%, Q 15); octyl, m. 150°, 15%, Q 2.5; allyl (2HCl, m. 257°, 3%, Q 20); 1-methylallyl (2HCl.1.75H2O, m. 95°); cyclohexyl (2HCl.0.25H2O, m. 252°, 30%, Q 30); 2-hydroxyethyl (2HCl.H2O, m. 182°, 15%, Q 3); 2-methoxyethyl (2HCl, m. 271°, Q 25); benzyl (2HCl, m. 270°, Q 16); (α-methylphenethyl) (2HCl.0.25H2O, m. 243°, 31%, Q 25); di-Me (2HCl, m. 290°, 85%, Q 6); N-ethyl-N-butyl(2HCl, m. 240°, 65%, Q 30); di-Pr, SN 13,835, m. 181°, 11%, Q 25; di-Bu, SN 14,105, m. 164°, 20%, Q 35; diiso-Bu (0.5H2O, m. 166°, 38%); diiso-Am (0.5H2O, m. 135°); dihexyl (2HCl, m. 220°, 40%, Q 0.5); diheptyl (2HCl, m. 203°, 52%, Q 1); dioctyl (2HCl, m. 192°, 46%, Q 0.2); bis(2-ethylhexyl) (2HCl.H2O, m. 154°, 1%, Q 3); methyl(2-hydroxyethyl) (2HCl, SN 12,363, m. 250°, 63%, Q 3); butyl(2-hydroxyethyl), SN 14,824, m. 149°, 22%, Q 12; bis(2-hydroxyethyl), m. 193°, 25%, Q 0.6; dibenzyl (2HCl, m. 235°, 74%, Q 2.5); N-methyl-N-Ph (H2O, m. 140°, 39%, Q 0.07); N-ethyl-N-Ph, m. 131°, 54%, Q <0.05. Further analogs of VII: α-1-piperidyl (2HCl.2.5H2O, SN 11,636, m. 302°, 77.5%, Q 25); α-(2-methyl-1-piperidyl) (2HCl, SN 12,357, m. 288°, 66%, Q 20); α-4-morpholinyl (2HCl, SN 11,987, m. 292°, 60-5%, Q 4). Compounds containing heterocyclic nuclei other than the 4-quinolyl include the following 4-(heterocyclic amino)-α-diethylamino-ο-cresols: 9-acridyl (2HCl, SN 12,356, m. 265°, 45%, Q 1.5); (3-chloro-9-acridyl) (2HCl, SN 12,355, m. 267°, 52%, Q 3); (4-methoxy-9-acridyl) (2HCl, SN 12,164, m. 245°, 50%, Q 0.15); (3-chloro-5-methyl-9-acridyl) (2HCl, SN 11,988, m. 275°, 40%, Q 0.25); 2-quinolyl (2HCl, SN 9559, m. 230°, 48%, Q 0.12); (6-methoxy-2-quinolyl) (2HCl, SN 11,537, m. 237°, 20.5%, Q 0.7); (5-nitro-2-quinolyl) (2HCl, SN 9307, m. 245°, 33%, Q <0.07); (2-amino-4-pyrimidyl) (2HCl, SN 9591, m. 258°, 41%, Q 1.1); [2-(1-piperidyl)-4-pyrimidyl], SN 10,177, m. 156°, 31%, Q 0.4; (2-amino-6-methyl-4-pyrimidyl) (2HCl, m. 245°, 55%); (4-methoxy-2-benzothiazolyl) (2HCl, SN 11,189, m. 163°, 47%, Q <0.07); (6-chloro-2-methoxy-9-acridyl) (VIII), SN 8617, m. 175°, 50% (H2O, m. 117°; 2HCl, m. 280°, 76%, Q 4; 2HCl.2H2O, m. 180°); analogs of VIII: α-(ethylbutylamino) (2HCl, m. 252°, 36%, Q 5); α-dibutylamino (2HCl, SN 11,599, m. 246°, 69%, Q 2.5); α-diallylamino, SN 13,163, m. 158°, 16%, Q 0.5; α-dihexylamino (2HCl, m. 254°, 23%, Q 0.4); α-dioctylamino (2HCl, m. 285°, 20%, Q <0.06); α-1-piperidylamino (2HCl, SN 11,536, m. 287°, Q 0.6); α-hexylamino (2HCl.H2O, m. 226°, 7%, Q 1); α-(2-hydroxyethylamino) (2HCl.H2O, SN 11,233, m. 284°, 90%, Q 0.2); α-benzamido (HCl.0.5H2O, SN 11,589, m. 294°, 95%, Q <0.04). 5-(6-Chloro-2-methoxy-9-acridylamino)-α-diethylamino-ο-cresol (2HCl.0.5H2O, SN 9614, m. 237°, 50%, Q 1); 4-tert-butyl-6-(6-chloro-2-methoxy-9-acridylamino)-α-diethylamino-ο-cresol (IX) (2HCl, SN 11,544, m. 271°, 98%, Q 0.6); 4-Ph analog of IX (2HCl, SN 11,553, m. 274°, 84%, Q 0.5); 4-diethylaminomethyl analog of IX (3HCl.H2O, SN 11,550, m. 257°, 73%, Q 2); 6-allyl-4-(6-chloro-2-methoxy-9-acridylamino)-α-diethylaminο-ο-cresol (X) (2HCl, SN 11,234, m. 233°, 65%, Q 3); α-diallylamino analog of X (2HCl.H2O, SN 13,399, m. 188°, 12%, Q 0.3); and α-1-piperidyl analog of X, SN 12,701, m. 164°, 44%, Q 2. A series of nitrobenzylamines was prepared by condensation of the nitrobenzyl chloride with the amine in absolute EtOH. During the course of this work, 2-(chloromethyl)-4-nitrophenetole,m. 72-5°, was obtained in 75% yield from the chloromethylation of 4-nitrophenetole. The nitrobenzylamines were reduced catalytically in absolute EtOH and the resulting aminobenzylamines without isolation were condensed with the chloroheterocycle. Thus were obtained: N,N-diethyl-3-nitrobenzylamine, b6 145-8°, 60%; 4-nitro isomer (XI) (HCl, m. 162°, 45%); analogs of XI: N,N-di-Pr (HCl, m. 138°, 68%); N-monoisopropyl (HCl, m. 232°, 82%); N-monoisobutyl (HCl, m. 214°, 64%). N,N-Diethyl-5-nitro-2-methoxybenzylamine (XII) (HCl, m. 178°, 72%); analogs of XII: N-monoisobutyl (HCl, m. 176°, 63%); N-monoamyl (HCl salt could not be separated from an impurity of AmNH2.HCl). N,N-Diethyl-5-nitro-2-ethoxybenzylamine (HCl, m. 182°, 56%). 3-(7-Chloro-4-quinolylamino)-N,N-diethylbenzylamine (2HCl.2H2O, SN 11,590, m. 128° (all these HCl salts m. with decomposition), 85%, Q 1); 4-(7-chloro-4-quinolylamino)-N,N-diethylbenzylamine (XIII) (2HCl, SN 12,455, m. 261°, Q 4); N,N-di-Pr analog of XIII (2HCl, m. 255°, 60%, Q 4); the N-monoisopropyl analog of XIII (2HCl salt, m. 303°, 23%, Q 10); N-monoisobutyl analog of XIII (2HCl.H2O, m. 288°, 76%); 5-(7-chloro-4-quinolylamino)-N,N-diethyl-2-methoxybenzylamine (XIV), m. 203°, 64%, Q 25; N-monoisobutyl analog of XIV (2HCl.0.25H2O, m. 194°, 76%, Q 17); N-monoamyl analog of XIV (2HCl, m. 288°, 42%, Q 15); 2-ethoxy analog of XIV (2HCl.2H2O, m. 247°, 73%, Q 8); 3-(6-chloro-2-methoxy-9-acridylamino)-N,N-diethylbenzylamine (XV) (2HCl.0.75H2O, SN 10,984, m. 278°, 55%, Q 0.5); the 4-substituted benzyl isomer of XV (2HCl.0.5H2O, SN 10,028, m. 260°, 92%, Q 0.4); and 5-(6-chloro-2-methoxy-9-acridylamino)-2-methoxy-N,N-diethylbenzylamine (2HCl.0.5H2O, m. 212°, 67%, Q 3). 6-Chloro-9-(4-hydroxyanilino)-2-methoxyacridine, m. 266° (decomposition) (HCl, orange, m. above 300°, prepared in 98% yield from p-NH2C6H4OH and 6,9-dichloro-2-methoxyacridine on the steam bath), failed to undergo the usual Mannich reaction. Failure of this reaction led to the development of the method of synthesis used for all of the heterocyclic derivatives reported in this paper. If you want to learn more about this compound(4-Chloro-8-methylquinoline)SDS of cas: 18436-73-2, you may wish to communicate with the author of the article,or consult the relevant literature related to this compound(18436-73-2).

Reference:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Serwa, Remigiusz; Nam, Tae-gyu; Valgimigli, Luca; Culbertson, Sean; Rector, Christopher L.; Jeong, Byeong-Seon; Pratt, Derek A.; Porter, Ned A. published the article 《Preparation and Investigation of Vitamin B6-Derived Aminopyridinol Antioxidants》. Keywords: aminopyridinol preparation antioxidant.They researched the compound: 5-(hydroxymethyl)-2,4-dimethylpyridin-3-ol hydrochloride( cas:148-51-6 ).Quality Control of 5-(hydroxymethyl)-2,4-dimethylpyridin-3-ol hydrochloride. Aromatic heterocyclic compounds can be divided into two categories: single heterocyclic and fused heterocyclic. In addition, there is a lot of other information about this compound (cas:148-51-6) here.

3-Pyridinols bearing amine substitution para to the hydroxylic moiety have previously been shown to inhibit lipid peroxidation more effectively than typical phenolic antioxidants, for example, α-tocopherol. We report here high-yielding, large-scale syntheses of mono- and bicyclic aminopyridinols from pyridoxine hydrochloride (i.e., vitamin B6). This approach provides straightforward, scaleable access to novel, potent, mol. scaffolds whose antioxidant properties have been investigated in homogeneous solutions and in liposomal vesicles. These mol. aggregates mimic cell membranes that are the targets of oxidative damage in vivo.

If you want to learn more about this compound(5-(hydroxymethyl)-2,4-dimethylpyridin-3-ol hydrochloride)Quality Control of 5-(hydroxymethyl)-2,4-dimethylpyridin-3-ol hydrochloride, you may wish to communicate with the author of the article,or consult the relevant literature related to this compound(148-51-6).

Reference:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Lee, Hyunji; Kim, Dong-Guk; Banskota, Suhrid; Lee, You Kyoung; Nam, Tae-gyu; Kim, Jung-Ae; Jeong, Byeong-Seon published an article about the compound: 5-(hydroxymethyl)-2,4-dimethylpyridin-3-ol hydrochloride( cas:148-51-6,SMILESS:OC1=C(C)C(CO)=CN=C1C.[H]Cl ).Electric Literature of C8H12ClNO2. Aromatic heterocyclic compounds can be classified according to the number of heteroatoms or the size of the ring. The authors also want to convey more information about this compound (cas:148-51-6) through the article.

We recently developed an efficient and practical synthesis for a novel series of pyridoxine-derived 6-amido-2,4,5-trimethylpyridin-3-ols and found that this novel scaffold has outstanding activity to inhibit angiogenesis measured by the quant. chick embryo chorioallantoic membrane (CAM) assay. As an effort to extend the scope of the amidopyridinol scaffold, we here report the synthesis and antiangiogenic activities of a series of bicyclic versions of the amidopyridinol including five- and six-membered cyclic amide-, cyclic urea-, and cyclic carbamate-fused pyridinols. The six membered bicyclic derivatives were prepared by the reported procedures, and the five-membered ring-fused ones were synthesized by new synthetic methods developed in this study. CAM assays showed that both six- and five-membered lactam-fused pyridinols have activities comparable to sunitinib malate, the pos. control, in inhibition of vascular endothelial growth factor-induced angiogenesis. On the other hand, the urea and the carbamate derivatives showed modest to moderate antiangiogenic activities. In summary, some bicyclic aminopyridinols can provide a good platform for structural exploitation in future medicinal chem. work.

If you want to learn more about this compound(5-(hydroxymethyl)-2,4-dimethylpyridin-3-ol hydrochloride)Electric Literature of C8H12ClNO2, you may wish to communicate with the author of the article,or consult the relevant literature related to this compound(148-51-6).

Reference:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

SDS of cas: 591-12-8. Aromatic heterocyclic compounds can also be classified according to the number of heteroatoms contained in the heterocycle: single heteroatom, two heteroatoms, three heteroatoms and four heteroatoms. Compound: 5-Methylfuran-2(3H)-one, is researched, Molecular C5H6O2, CAS is 591-12-8, about Catalytic C-C coupling of furanic platform chemicals to high carbon fuel precursors over supported ionic liquids. Author is Gebresillase, Mahlet N.; Seo, Jeong Gil.

Imidazolium-based ionic liquid (IL) catalysts with different anions (Cl-, HSO4-, and CF3SO3-) were covalently anchored to the surface of fibrous silica (FS) by using alkyl chains as a linker. The prepared catalysts were applied for the C-C coupling reactions of 2-methylfuran (2-MF) with levulinic acid (LA), angelica lactone (AL), and Et levulinate (EL) to synthesize high carbon fuel precursors. The hydrophilic nature of FS supported IL catalyst having bisulfate anion was suitable for the self C-C coupling reaction of 2-MF and the reaction of 2-MF with LA. FS supported IL catalyst having triflate anion (FS-ILCF3SO3) exhibited high conversion and selectivity for the target fuel precursors from the C-C coupling reaction of 2-MF with AL and EL. The increased solubility, tunable acidity, and hydrophilicity/hydrophobicity of FS-ILHSO4 and FS-ILCF3SO3 promise a sustainable catalyst system. Supported ILs make the transformation processes greener and more efficient for large-scale production of biomass-derived fuel precursors.

If you want to learn more about this compound(5-Methylfuran-2(3H)-one)SDS of cas: 591-12-8, you may wish to communicate with the author of the article,or consult the relevant literature related to this compound(591-12-8).

Reference:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

The reaction of an aromatic heterocycle with a proton is called a protonation. One of articles about this theory is 《Barriers to Cervical Cancer Screening in Geneva (DEPIST Study).》. Authors are Catarino, Rosa R; Vassilakos, Pierre P; Royannez-Drevard, Isabelle I; Guillot, Cécile C; Alzuphar, Stéphanie S; Fehlmann, Aurore A; Meyer-Hamme, Ulrike U; Petignat, Patrick P.The article about the compound:5-(hydroxymethyl)-2,4-dimethylpyridin-3-ol hydrochloridecas:148-51-6,SMILESS:OC1=C(C)C(CO)=CN=C1C.[H]Cl).Recommanded Product: 148-51-6. Through the article, more information about this compound (cas:148-51-6) is conveyed.

OBJECTIVES: Cervical screening is only efficient if a large part of eligible women participate. Our aim was to identify sociodemographic barriers to cervical screening and consider self-reported reasons to postpone screening. METHODS: Between September 2011 and June 2015, a questionnaire addressing reasons for nonparticipation in cervical screening was completed by 556 women who had not undergone a Pap test in the preceding 3 years. Pearson χ test was used to analyze differences between subgroups. Logistic regression was used to explore the association between sociodemographic characteristics and reasons for nonparticipation. RESULTS: The main reasons for nonparticipation in cervical cancer screening were practical barriers, such as lack of time and the cost of screening. These barriers were more likely to be reported by working women, women who were not sexually active, and those without health insurance. Younger women, non-European women living in Switzerland, and childless women were more likely to have never participated in a screening program before (adjusted odds ratio [aOR], 3.15; 95% CI, 1.41-6.98; aOR, 2.76; 95% CI, 1.48-5.16; aOR, 1.74; 95% CI, 1.03-2.99, respectively). CONCLUSIONS: Practical considerations seem to play a more important role in screening participation than emotional reasons and other beliefs. Particular attention should be paid to immigrant communities, where women seem more likely to skip cervical screening.

If you want to learn more about this compound(5-(hydroxymethyl)-2,4-dimethylpyridin-3-ol hydrochloride)Recommanded Product: 148-51-6, you may wish to communicate with the author of the article,or consult the relevant literature related to this compound(148-51-6).

Reference:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Quality Control of 5-Chloro-4-iodopyridin-2-amine. Aromatic heterocyclic compounds can also be classified according to the number of heteroatoms contained in the heterocycle: single heteroatom, two heteroatoms, three heteroatoms and four heteroatoms. Compound: 5-Chloro-4-iodopyridin-2-amine, is researched, Molecular C5H4ClIN2, CAS is 1260667-65-9, about From Milligram to Kilogram Manufacture of AZD4573: Making It Possible by Application of Enzyme-, Iridium-, and Palladium-Catalyzed Key Transformations. Author is Karlsson, Staffan; Benson, Helen; Cook, Calum; Currie, Gordon; Dubiez, Jerome; Emtenaes, Hans; Hawkins, Janet; Meadows, Rebecca; Smith, Peter D.; Varnes, Jeffrey.

With the first generation medicinal chem. synthesis as a starting point, herein process development of AZD4573, an oncol. drug candidate was described. In addition to improved yields and removal of chromatog. steps, other factors such as availability of starting materials as well as safety of the chem. involved were addressed. With several steps involving volatile, reactive, and non-UV active materials, reaction optimization was facilitated by implementing off-line 1H NMR anal. of crude mixtures Key transformations targeted for process development included a Wolff-Kishner reduction, an iridium-catalyzed borylation, and enzymic resolution of a racemic amino-ester.

If you want to learn more about this compound(5-Chloro-4-iodopyridin-2-amine)Quality Control of 5-Chloro-4-iodopyridin-2-amine, you may wish to communicate with the author of the article,or consult the relevant literature related to this compound(1260667-65-9).

Reference:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

The reaction of an aromatic heterocycle with a proton is called a protonation. One of articles about this theory is 《4,5-Dihalo and 3-amino analogs of pyridoxine. New route to 4-deoxypyridoxine》. Authors are McCasland, G. E.; Gottwald, L. Kenneth; Furst, Arthur.The article about the compound:5-(hydroxymethyl)-2,4-dimethylpyridin-3-ol hydrochloridecas:148-51-6,SMILESS:OC1=C(C)C(CO)=CN=C1C.[H]Cl).Related Products of 148-51-6. Through the article, more information about this compound (cas:148-51-6) is conveyed.

Dihalo analogs of pyridoxine, expected to show good alkylating activity, were prepared as potential antitumor agents. SOCl2 (15.0 ml.) was added to 2.06 g. powd. dry pyridoxine hydrochloride (I), the mixture refluxed 1 hr., cooled to 0-25° for several days, filtered, and the crystals washed with C6H6, then with 10 ml. Me2CO, m. 140-90°. Recrystallization from absolute EtOH-C6H6 gave 1.6 g. needles. Dissolution in 25 ml. boiling absolute EtOH and treatment with 25 ml. hot C6H6 gave on cooling 0.9 g. 2-methyl-3-hydroxy-4,5-bis(chloromethyl)pyridine hydrochloride (II), m. 175-90° (decomposition), recrystallized from 10 ml. EtOH to yield 0.7 g. product, m.p. unchanged. I (6.2 g.) treated with 43.5 ml. SOCl2 but kept at 25° only 12 hrs. gave after washing with Me2CO 7.1 g. II, m. 185-95° (decomposition). The use of PCl5 in CCl4, or concentrated HCl, failed to yield pure II. I (21.4 g.) and 200 ml. 8.8M HBr was refluxed 15 min., cooled, filtered, and the solid washed with H2O and Me, CO to give 24.2 g. crystalline 2methyl-3-hydroxy-4,5-bis(bromomethyl)pyridine hydrobromide (III), m. 224-8° (decomposition). III (1.88 g.) was stirred with 0.463 g. NaHCO3 in 20 ml. H2O; the mixture turned pink, then red, and after 100 min. stirring was filtered. The solid was washed with H2O and dried to give 0.6 g. brown-red powder, m. above 325°. The pH of the filtrate was 2, indicating displacement of one or both Br atoms from BrCH2. The solid was insoluble at the boiling point in EtOH, H2O, or 6M HCl. I (2.06 g.) boiled with 67.2 g. 7.6M HI gave 1.3 g.2-methyl-3-hydroxy-4,5-bis(iodomethyl)pyridine hydriodide (IV), m. 120-60° (decomposition). III with NaI in Me2CO failed to give IV. 2-Methyl-3-amino-4,5-bis(hydroxymethyl)pyridine monohydrochloride (V), m. 195-7°, with 8.8M HBr gave 34% 2 methyl-3-amino4,5-bis(bromomethyl)pyridine hydrobromide, m. 220° (decomposition). When 1.0 g. V was boiled with 6.5 ml. 7.6M HI, iodine was liberated and one of the HOCH2 groups was reduced to Me to give 0.59 g. black crystalline mass, which was crystallized from absolute EtOH to yield light yellow 2,4-dimethyl-3-amino-5-(hydroxymethyl)pyridine hydriodide (VI), m. 190-6°, VI (50 mg.) was heated 5 min. with 43 mg. AgCl in 1.0 ml. H2O, the mixturefiltered to remove AgI, the filtrate acidified with 0.2 ml. 12M HCl, the acid solution treated with 23 mg. NaNO2 in 1.0 ml. H2O, and the mixture heated until N effervescence ceased (10-15 min.). The solution was vacuum-distilled to dryness, 0.5 ml. 12M HCl added to the residue, the distillation to dryness repeated, the residue extracted with 2.0 ml. absolute EtOH, cooled, and filtered. The filtrate was treated with Et2O and the separated crystals collected and dried to yield 10 mg. 4-deoxypyridoxine hydrochloride, m. 255° (decomposition). V (1.0 g.), 0.8 g. fused NaOAc, and 20 ml. Ac2O was boiled 20 min., the solvent removed by vacuum distillation, the residue extracted with 15 ml. CHCl3, the CHCl3 extract treated with C, and evaporated to give a brown oil, which was stirred with 2.0 ml. Et2O to yield 0.4 g. solid 2-methyl-3-acetamido-4,5-bis(acetoxymethyl)pyridine (VII), m. 103-1° (C6H6). VII (0.42 g.) in 12 ml. 0.5M NaOH was kept 2 hrs. at 20°, the clear solution adjusted to pH 6-7 by addition of HOAc, the solvent evaporated in vacuo, the residue extracted (Soxhlet) 24 hrs. with Me2CO, and the extract cooled to give 0.1 g. crystalline 2-methyl-3-acetamido-4,5-bis(hydroxymethyl)pyridine, m. 185-6°.

If you want to learn more about this compound(5-(hydroxymethyl)-2,4-dimethylpyridin-3-ol hydrochloride)Related Products of 148-51-6, you may wish to communicate with the author of the article,or consult the relevant literature related to this compound(148-51-6).

Reference:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Recommanded Product: 1260667-65-9. The fused heterocycle is formed by combining a benzene ring with a single heterocycle, or two or more single heterocycles. Compound: 5-Chloro-4-iodopyridin-2-amine, is researched, Molecular C5H4ClIN2, CAS is 1260667-65-9, about Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies. Author is Barlaam, Bernard; Casella, Robert; Cidado, Justin; Cook, Calum; De Savi, Chris; Dishington, Allan; Donald, Craig S.; Drew, Lisa; Ferguson, Andrew D.; Ferguson, Douglas; Glossop, Steve; Grebe, Tyler; Gu, Chungang; Hande, Sudhir; Hawkins, Janet; Hird, Alexander W.; Holmes, Jane; Horstick, James; Jiang, Yun; Lamb, Michelle L.; McGuire, Thomas M.; Moore, Jane E.; O’Connell, Nichole; Pike, Andy; Pike, Kurt G.; Proia, Theresa; Roberts, Bryan; San Martin, Maryann; Sarkar, Ujjal; Shao, Wenlin; Stead, Darren; Sumner, Neil; Thakur, Kumar; Vasbinder, Melissa M.; Varnes, Jeffrey G.; Wang, Jianyan; Wang, Lei; Wu, Dedong; Wu, Liangwei; Yang, Bin; Yao, Tieguang.

A CDK9 inhibitor having short target engagement would enable a reduction of Mcl-1 activity, resulting in apoptosis in cancer cells dependent on Mcl-1 for survival. We report the optimization of a series of amidopyridines (from compound 2), focusing on properties suitable for achieving short target engagement after i.v. administration. By increasing potency and human metabolic clearance, we identified compound 24, a potent and selective CDK9 inhibitor with suitable predicted human pharmacokinetic properties to deliver transient inhibition of CDK9. Furthermore, the solubility of 24 was considered adequate to allow i.v. formulation at the anticipated ED. Short-term treatment with compound 24 led to a rapid dose- and time-dependent decrease of pSer2-RNAP2 and Mcl-1, resulting in cell apoptosis in multiple hematol. cancer cell lines. Intermittent dosing of compound 24 demonstrated efficacy in xenograft models derived from multiple hematol. tumors. Compound 24 is currently in clin. trials for the treatment of hematol. malignancies.

If you want to learn more about this compound(5-Chloro-4-iodopyridin-2-amine)Recommanded Product: 1260667-65-9, you may wish to communicate with the author of the article,or consult the relevant literature related to this compound(1260667-65-9).

Reference:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia